# To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years

> **NCT04618640** · PHASE3 · UNKNOWN · sponsor: **Boryung Biopharma Co., Ltd.** · enrollment: 249 (estimated)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Poliomyelitis

## Interventions

- **BIOLOGICAL:** DTaP-IPV combination vaccine

## Key facts

- **NCT ID:** NCT04618640
- **Lead sponsor:** Boryung Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-26
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-07-30
- **Target enrollment:** 249 (ESTIMATED)
- **Last updated:** 2020-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04618640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04618640, "To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04618640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*